MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2022 International Congress

    Awake Bruxism, a case series of an underrecognized disorder

    I. Trigo, B. Solano Vila, D. Domínguez (Girona, Spain)

    Objective: We present a series of 3 cases with Awake Bruxism (AB) and frontal dysfunction. Background: AB is an infrequent, daytime form of bruxism, described…
  • 2022 International Congress

    Pseudodystonia due to Palmaris Brevis Syndrome: Case Report

    D-Y. Liou, A. Alamoudi, D. Preston, C. Kilbane (Cleveland, USA)

    Objective: We describe a case of pseudodystonia caused by palmaris brevis syndrome. Background: Palmaris brevis (PB) syndrome is a pseudodystonia characterized by spontaneous, involuntary, nonpainful…
  • 2022 International Congress

    Botulinum Toxin Outcomes in Patients with Lower Limb Dystonia

    M. Wajid, J. Frey, L. Kugler, T. Stiep, J. Yu, J. Toledo, J. Lopes, A. Ramirez-Zamora, A. Rawls, A. Wagle Shukla, I. Malaty (Gainesville, USA)

    Objective: To assess botulinum toxin outcomes in patients with lower limb dystonia. Background: One of the most effective treatments for dystonia is botulinum toxin (BoNT)…
  • 2022 International Congress

    Development of a patient journey map for people living with cervical dystonia

    M. Benson, A. Albanese, K. Bhatia, P. Cavillon, L. Cuffe, K. König, C. Reinhard, H. Graessner (Brussels, Belgium)

    Objective: As part of the ongoing European Reference Networks for Rare Neurological Diseases (ERN-RND) program, we aimed to develop a cervical dystonia patient journey map…
  • 2022 International Congress

    A bitter syndrome as a cause of refractory movement disorders

    DD. García-Meléndez, F. Muñoz Escudero, MI. Morales-Casado, P. Lobato Casado, AM. Diezma Martín, G. Tabar Comellas, N. Sánchez Cano, B. Canovas Gaillemin, N. López Ariztegui (Toledo, Spain)

    Objective: Submit a case of GLUT-1 deficiency for consideration in the differential diagnosis of movement disorders and refractory epilepsies because early treatment will prevent progressive…
  • MDS Virtual Congress 2021

    Dystonia gravidarum: An emerging clinical entity

    E. Donlon, P. Moloney, S. Smyth, S. Lyons, T. Lynch, E. Mcgovern (Limerick, Ireland)

    Objective: We describe a case of cervical dystonia in a 36 year-old, secundigravid, Caucasian woman at 8 weeks gestation. Background: Though uncommon, primary movement disorders…
  • MDS Virtual Congress 2021

    Benefits of Treatment with OnabotulinumtoxinA in Naive and Non-naive Patients with Cervical Dystonia are Sustained over Time: Preliminary Completer Analysis from CD PROBE

    P. Agarwal, M. Schwartz, A. Zuzek, A. Patel (Kirkland, USA)

    Objective: This analysis evaluated the sustained effects of onabotulinumtoxinA in patients with CD who were naive or non-naive to botulinum toxin at enrollment in CD…
  • MDS Virtual Congress 2021

    Post-stroke dystonia: Three unique cases

    C. Han, L. Klebanoff, P. Magda, B. Sadoughi, S. Pullman, H. Sarva (Ny, USA)

    Objective: Describing 3 unique post-stroke dystonia cases. Background: Dystonia, the 2nd most common post-stroke movement disorder, presents commonly contralateral to the lesion, focally, and 9.5…
  • MDS Virtual Congress 2021

    Impact of Disease Severity on Presentation Subtype and OnabotulinumtoxinA Utilization in Patients with Cervical Dystonia: Results from the CD PROBE Completer Population

    P. Agarwal, R. Barbano, H. Moore, M. Schwartz, A. Zuzek, A. Patel (Kirkland, USA)

    Objective: Examine the impact of cervical dystonia (CD) severity on presentation subtype and onabotulinumtoxinA utilization in the completer population from the CD PROBE study. Background:…
  • MDS Virtual Congress 2021

    Botulinum injections for idiopathic cervical dystonia: a longitudinal study

    G. Yahalom, T. Fay-Karmon, V. Livneh, S. Israeli-Korn, L. Ephraty, S. Hassin-Baer (Jerusalem, Israel)

    Objective: In this retrospective longitudinal study, we explored the efficacy of repeated BT injection sessions for idiopathic cervical dystonia (ICD). Background: Botulinum toxin (BT) injections…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley